Alignment with FDA on Registration Path for CRB-701 in 2L HNSCC and Cervical Cancer Announced April 15, 2026
CT-P71 received Fast Track Designation from US FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma April 15, 2026
Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma April 15, 2026
